National Comprehensive Cancer Network

The NCCN ORP has received millions of dollars in research grants from major pharmaceutical companies to support investigator-initiated trials, which explore new venues of clinical investigation that answer important scientific questions. Studies evaluate innovative combinations and sequencing regimens of drugs, mechanisms of action of specific agents, or drug resistance or are directed toward exploring extended uses for specific agents.

NCCN has received the following grants to support investigator-initiated trials:

Abraxis BioScience, Inc. and AstraZeneca – $2,075,000 for clinical studies of paclitaxel, albumin-bound
Allos Therapeutics, Inc. – $2,300,000 for clinical studies of pralatrexate
Bristol-Myers Squibb Company and ImClone Systems Incorporated – $3,355,232 for clinical studies of cetuximab in head and neck cancers and bladder cancers
Cephalon, Inc. – $1,391,193 for clinical studies of bendamustine
GlaxoSmithKline LLC – $4,000,000 for clinical studies of pazopanib and ofatumumab
Merck & Co., Inc. – $1,046,380 for clinical studies of vorinostat
Pfizer, Inc. – $3,150,000 for clinical studies of irinotecan and celecoxib
Pfizer, Inc. – $2,000,000 for preclinical and specialized imaging studies of sunitinib
Pfizer, Inc. – $2,100,000 for clinical studies of axitinib
Roche Laboratories, Inc. – $2,500,000 for clinical studies of capecitabine
Wyeth – $4,150,000 for clinical studies of temsirolimus

Clinical Studies for Irinotecan
Clinical Studies for Celecoxib
Clinical Studies for Capecitabine
Preclinical Studies for Sunitinib
Specialized Imaging Studies for Sunitinib
Clinical Studies for Abraxane®
Clinical Studies for Cetuximab
Clinical Studies for Bendamustine
Clinical Studies for Vorinostat
Clinical Studies for Temsirolimus
Clinical Studies for Pralatrexate
Clinical Studies for Pazopanib
Clinical Studies for Ofatumumab
Clinical Studies for Axitinib

Clinical Studies for Irinotecan

INVESTIGATOR	MEMBER INSTITUTION	STUDY
Patrick J. Creaven, MD, PhD	Roswell Park Cancer Institute	Phase I Study of Irinotecan followed by Capecitabine in Patients with Advanced Breast Carcinoma
Stacy Moulder, MD	H. Lee Moffitt Cancer Center & Research Institute	A Single Arm Phase II Study of Gemcitabine and Irinotecan in Patients with Metastatic Breast Cancer
Pedro Ramirez, MD	The University of Texas MD Anderson Cancer Center	Phase I Trial of Concurrent Weekly CPT-11, Cisplatinum, and Radiotherapy for Patients with Newly Diagnosed Stage IIIb-IVa Cancer of the Uterine Cervix
M. Wasif Saif, MD, MBBS	University of Alabama at Birmingham Comprehensive Cancer Center	A Phase I and Pharmacologic Trial of Sequential Administration of Bi-weekly Gemcitabine as a 24-hour IV Infusion followed by Irinotecan as a 24-hour IV Infusion in Adult Cancer Patients
Charles Shapiro, MD	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	Phase II Study of Sequentially Administered Mitomycin and Irinotecan in Patients with Refractory Metastatic and Inflammatory Breast Cancers

Clinical Studies for Celecoxib

INVESTIGATOR	MEMBER INSTITUTION	STUDY
Manuel Hidalgo, MD, PhD	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Biological Evaluation of Celecoxib in Pancreatic Cancer
Milind Javle, MD	Roswell Park Cancer Institute	Celecoxib in Combination with Irinotecan (CPT-11), 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer: A Phase I Study
Ritsuko Komaki, MD, FACR	The University of Texas MD Anderson Cancer Center	A Phase I Study of Concurrent CPT-11/Cisplatin and Celecoxib with Radiation Therapy for Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC)
Nancy Lewis, MD	Fox Chase Cancer Center	A Randomized Trial of Celecoxib +/- Rosiglitazone vs. Placebo in Patients with Early Stage Non-Invasive Bladder Carcinoma
Brian Rini, MD	UCSF Helen Diller Family Comprehensive Cancer Center	A Phase II Trial of Celecoxib Plus Interferon-Alpha in Advanced Renal Cell Carcinoma
Manisha Shah, MD	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma
Charles Shapiro, MD	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	A Phase II Trial of Exemestane (Aromasin) in Combination with Celecoxib (Celebrex) as Neoadjuvant Treatment in Postmenopausal Women with Stage II, III, and IV Breast Cancer
Przemyslaw Twardowski, MD	City of Hope Comprehensive Cancer Center	Biologic Markers of Angiogenesis: A Companion Study to Phase I Trial of Oral Etoposide in Combination with Celecoxib in Patients with Advanced Malignancies and Phase I Trial of Oral Cyclophosphamide in Combination with Celecoxib in Patients with Advanced Malignancies

Clinical Studies for Capecitabine

INVESTIGATOR	MEMBER INSTITUTION	STUDY
Tanios Bekaii-Saab, MD	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients with Advanced Pancreatic Cancer
Renuka Iyer, MD	Roswell Park Cancer Institute	Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer
Nikhil Khushalani, MD	Roswell Park Cancer Institute	Phase II Study of Capecitabine in Combination with Oxaliplatin and Radiotherapy for Esophageal and Gastroesophageal Junction Cancer
Andrew Ko, MD/Kimberly Jones, MD	UCSF Helen Diller Family Comprehensive Cancer Center/Huntsman Cancer Institute at the University of Utah	A Phase I Study, with expanded cohort, of Biweekly Fixed-Dose Rate Gemcitabine plus Capecitabine in Patients with Advanced Pancreatic and Biliary Carcinomas
Daniel Laheru, MD	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Thymidylate Synthase (TS) Genotype-Directed Phase II Trial of Oral Capecitabine for 2nd Line Treatment of Advanced Pancreatic Cancer
Mary Mulcahy, MD	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	A Phase II Study of Capecitabine and Oxaliplatin with Radiation for Esophageal and Gastroesophageal Junction Adenocarcinoma
Lakshmi Pendyala, PhD	Roswell Park Cancer Institute	Gene Expression Profiling of Esophageal Cancer in Patients Receiving Oxaliplatin, Capecitabine and Radiation, Exploring Correlations to Response
M. Wasif Saif, MD, MBBS	Yale University School of Medicine	A Phase I/II, Open-Label, Dose Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients with Advanced Pancreatic Carcinoma
Hope Uronis, MD	Duke Cancer Institute	Correlative Biomarker Proposal for A Phase II Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinoma
Robert Warren, MD	UCSF Helen Diller Family Comprehensive Cancer Center	A Retrospective Analysis of Thymidylate Synthase (TS) and Thymidine Phosphorylase (TP) Levels and Thymidylate Synthase (TS) Genetic Polymorphisms from Archived Hepatocellular Carcinoma (HCC) Surgical Specimens

Preclinical Studies for Sunitinib

INVESTIGATOR	MEMBER INSTITUTION	STUDY
Long Dang, MD, PhD	University of Michigan Comprehensive Cancer Center	Targeting Tumor Reactive Response to Antiangiogenic Therapy
Frank Fitzpatrick, PhD	Huntsman Cancer Institute at the University of Utah	Molecular Determinants of Sunitinib Efficacy
Roberto Pili, MD	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Vertical Inhibition of the VEGF Pathway with Sunitinib in Combination with HDAC and mTOR Inhibitors in Renal Cell Carcinoma Models
Sabina Signoretti, MD and James Mier, MD	Dana-Farber/Brigham and Women’s Cancer Center \| Massachusetts General Hospital Cancer Center	Therapy of Renal Cell Carcinoma with Sutent: Mechanism of Acquired Resistance
John Sunwoo, MD, FACS	Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine	Preclinical Evaluation of Sunitinib in Squamous Cell Carcinoma of the Head and Neck
Michael Wong, MD, PhD, FRCPC	Roswell Park Cancer Institute	Inhibition of Human Angiosarcoma and Reversal of Chemoresistance by Sunitinib
Sam Yoon, MD	Dana-Farber/Brigham and Women’s Cancer Center \| Massachusetts General Hospital Cancer Center	Sunitinib with and without Radiation Therapy: Analysis in a Novel Mouse Model of Soft Tissue Sarcomas

Specialized Imaging Studies for Sunitinib

INVESTIGATOR	MEMBER INSTITUTION	STUDY
John Hoffman, MD	Huntsman Cancer Institute at the University of Utah	Sunitinib for Metastatic Renal Cell Cancer with Imaging Biomarker Assessments for the Early Prediction of Tumor Response
Robert G. Maki, MD, PhD	Memorial Sloan-Kettering Cancer Center	18FDG-PET As a Means to Determine Clinical Response in Soft Tissue Sarcomas in Patients Receiving a Continuous Daily Dosing Schedule of Sunitinib
Andrew Quon, MD	Stanford Cancer Institute	Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Jennifer Specht, MD	Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance	DCE-MRI and FDG-PET with Kinetic Analysis to Monitor Breast Cancer Response to Neoadjuvant Sunitinib and Metronomic Chemotherapy

Clinical Studies for Abraxane®

INVESTIGATOR	MEMBER INSTITUTION	STUDY
Mihaela Cristea, MD	City of Hope Comprehensive Cancer Center	Phase I Trial of Intraperitoneal nab-paclitaxel (Abraxane®) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity
Grace Dy, MD	Roswell Park Cancer Institute	SPARC Expression in NSCLC is Correlated with Response to nab-paclitaxel
Matthew G. Fury, MD, PhD	Memorial Sloan-Kettering Cancer Center	Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane®) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients with Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Razelle Kurzrock, MD	The University of Texas MD Anderson Cancer Center	Phase I Trial of Hepatic Arterial Infusion of Abraxane with a Pharmacokinetic Study in Advanced Solid Cancer Patients with Predominant Hepatic Metastases
Thomas Olencki, DO	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	A Phase 2 Study of Weekly Infusion nab-paclitaxel (paclitaxel protein-bound particles for injectable suspension) in Patients with Unresectable and Metastatic Uveal Melanoma
Gregory A. Otterson, MD	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	Phase II Trial of Abraxane plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding from VEGF Directed Therapies
Jasgit Sachdev, MD	University of Tennessee Cancer Institute	Neoadjuvant Weekly nab-paclitaxel (Abraxane®) Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide with Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer

Clinical Studies for Cetuximab

COORDINATING CENTER/PROJECT CHAIR	PARTICIPATING MEMBER INSTITUTION/PRINCIPAL INVESTIGATOR	STUDY
University of Michigan Comprehensive Cancer Center/Maha Hussain, MD, FACP	City of Hope Comprehensive Cancer Center/Przemyslaw Twardowski, MD	Phase II Randomized Trial of Gemcitabine and Cisplatin with or without Cetuximab in Patients with Urothelial Carcinoma
	Huntsman Cancer Institute at the University of Utah/Neeraj Agarwal, MD
	Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/Evan Yu, MD
	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins/Mario Eisenberger, MD
	Robert H. Lurie Comprehensive Cancer Center of Northwestern University/Gary MacVicar, MD
	Roswell Park Cancer Institute/Ellis Levine, MD
	Stanford Cancer Institute/Sandy Srinivas, MD
	The University of Texas MD Anderson Cancer Center/Arlene Siefker-Radtke, MD
	Vanderbilt-Ingram Cancer Center/Igor Puzanov, MD
	PARTICIPATING NON-MEMBER INSTITUTION/PRINCIPAL INVESTIGATOR
	Boston Medical Center/Gretchen Gignac, MD
	Lahey Clinic/Christopher Tretter, MD
	University of Southern California/David I. Quinn, MBBS, PhD, FRACP
	Wayne State University/Karmanos Cancer Institute/Ulka Vaishampayan, MD
Memorial Sloan-Kettering Cancer Center/Matthew Fury, MD, PhD	City of Hope Comprehensive Cancer Center/Dean Lim, MD	A Phase II Randomized Study of Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
	Fox Chase Cancer Center/Ranee Mehra, MD
	Huntsman Cancer Institute at the University of Utah/Neeraj Agarwal, MD
	Robert H. Lurie Comprehensive Cancer Center of Northwestern University/Bruce Brockstein, MD
	H. Lee Moffitt Cancer Center & Research Institute/Tawee Tanvetyanon, MD
	University of Tennessee Cancer Institute/Furhan Yunus, MD
	UNMC Eppley Cancer Center at The Nebraska Medical Center/Sandeep Rajan, MD

Clinical Studies for Bendamustine

INVESTIGATOR	MEMBER INSTITUTION	STUDY
Marc C.Chamberlain, MD	University of Washington	A Phase II Study of Bendamustine (Cephalon, Inc.) in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)
John C. Grecula, MD	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy (SRT) for Patients with 1-3 Brain Metatases from Solid Malignancies
Rachel M. Layman, MD	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer
Edward Pan, MD	H. Lee Moffitt Cancer Center & Research Institute	Phase I Study of Bendamustine with Concurrent Whole Brain Radiation Therapy in Patients with Brain Metastases from Solid Tumors
Francisco Robert, MD/Rodolfo Bordoni, MD	University of Alabama at Birmingham Comprehensive Cancer Center/Georgia Cancer Specialists	Phase I/IIa Study of the Novel Combination of Bendamustine with Irinotecan Followed by Etoposide/Carboplatin in Chemonaive Patients with Extensive Stage Small Cell Lung Cancer
Apostolia-Maria Tsimberidou, MD, PhD	The University of Texas MD Anderson Cancer Center	A Phase I Study of Bendamustine and Bevacizumab for Patients with Advanced Cancers

Clinical Studies for Vorinostat

INVESTIGATOR	MEMBER INSTITUTION	STUDY
Emily Chan, MD, PhD	Vanderbilt-Ingram Cancer Center	Phase I Trial of Chemoradiation with Capecitabine and Vorinostat in Pancreatic Cancer
Griffith Harsh, MD	Stanford Cancer Institute	Phase I Trial of Vorinostat Concurrent with Stereotactic Radiotherapy in Treatment of Brain Metastases from Non-Small Cell Lung Cancer
Ranee Mehra, MD	Fox Chase Cancer Center	Phase I Study of the HDAC Inhibitor Vorinostat with Chemotherapy and Radiation Therapy for the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Theodoros N. Teknos, MD	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	A Phase I Trial of Vorinostat in the Treatment of Advanced Oropharyngeal Carcinoma of the Head and Neck

Clinical Studies for Temsirolimus

INVESTIGATOR	MEMBER INSTITUTION	STUDY
Jeffrey Allen, MD	University of Tennessee Cancer Institute	A Phase I/II Trial of the Combination of Cisplatin, Cetuximab, and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Andrew Armstrong, MD, ScM	Duke Cancer Institute	Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men with Castration Resistant Metastatic Prostate Cancer
Susana M. Campos, MD, MPH	Dana-Farber/ Brigham and Women's Cancer Center	A Phase I/IB Study of AZD2171 (Cediranib) and Temsirolimus in Patients with Advanced Gynecological Malignancies
Sarat Chandarlapaty, MD, PhD	Memorial Sloan-Kettering Cancer Center	A Phase I/II Trial of Temsirolimus plus Neratinib in Patients with Metastatic HER2-Amplified or Triple- negative Breast Cancer
Warren A. Chow, MD	City of Hope Comprehensive Cancer Center	Randomized, Phase II Trial of AZD6244 alone and AZD6244 plus Temsirolimus for Soft Tissue Sarcomas
Ira Dunkel, MD	Memorial Sloan-Kettering Cancer Center	Phase I Study of Perifosine with Temsirolimus for Recurrent Pediatric Solid Tumors
Matthew G. Fury, MD, PhD	Memorial Sloan-Kettering Cancer Center	A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
R. Kate Kelley, MD/Halla Nimeiri, MD	UCSF Helen Diller Family Comprehensive Cancer Center/Robert H. Lurie Comprehensive Cancer Center of Northwestern University	A Phase I/II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
David Loeb, MD, PhD	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase I/II Trial of Torisel® and Liposomal Doxorubicin in Patients with Advanced Soft Tissue and Bone Sarcomas
Eric Sherman, MD	Memorial Sloan-Kettering Cancer Center	Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Sandhya Srinivas, MD	Stanford Cancer Institute	Using Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients with Castration-Resistant Prostate Cancer

Clinical Studies for Pralatrexate

INVESTIGATOR	MEMBER INSTITUTION	STUDY
Marcela G. del Carmen, MD, MPH	Massachusetts General Hospital Cancer Center	Phase I/II Study of Carboplatin and Pralatrexate in Patients with Recurrent Platinum Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Jean L. Grem, MD	UNMC Eppley Cancer Center at The Nebraska Medical Center	A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-Hour Infusion of 5-Fluorouracil Given Every Other Week in Adult Patients with Solid Tumors
Alan L. Ho, MD, PhD	Memorial Sloan-Kettering Cancer Center	A Multi-Institution Phase II Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Nihkil I. Khushalani, MD	Roswell Park Cancer Institute	Pralatrexate in Combination with Oxaliplatin in Advanced Esophago-Gastric Cancer: A Phase II Trial with Predictive Molecular Correlates
Michaela Liedtke, MD	Stanford Cancer Institute	A Phase I Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma
Jeffrey S. Rose, MD	The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute	Phase II Study of Pralatrexate and Docetaxel in Patients with Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-Based Therapy

Clinical Studies for Pazopanib

INVESTIGATOR	MEMBER INSTITUTION	STUDY
Nilofer S. Azad, MD/Razelle Kurzrock, MD	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins/The University of Texas MD Anderson Cancer Center	A Phase I Study Determining the Safety and Tolerability of Combination Therapy with Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK 1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched with Patients with Advanced Differentiated Thyroid Cancer
Laura QM Chow, MD	University of Washington/Seattle Cancer Care Alliance	A Phase I Clinical Trial of Pazopanib in Combination with Escalating Doses of Radioactive 131I in Patients with Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake
Herbert I. Hurwitz, MD	Duke Cancer Institute	Phase I Dose Escalation of Pazopanib Plus TH302 in Advanced Solid Tumors
Halla Nimeiri, MD	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumor (PNET)
William D. Tap, MD	Memorial Sloan-Kettering Cancer Center	A Phase IB/II Study of Gemcitabine and Docetaxel in Combination with Pazopanib (gem/doce/pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Margaret von Mehren, MD	Fox Chase Cancer Center	Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma
Jennifer J. Wheler, MD	The University of Texas MD Anderson Cancer Center	Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy

Clinical Studies for Ofatumumab

INVESTIGATOR	MEMBER INSTITUTION	STUDY
Seema Bhat, MD	Roswell Park Cancer Institute	A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia
Jennifer Brown, MD, PhD	Dana-Farber Cancer Institute	Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL
Alessandra Ferrajoli, MD	The University of Texas MD Anderson Cancer Center	Phase II Study of Ofatumumab as front-line treatment in elderly, unfit patients with Chronic Lymphocytic Leukemia (CLL)
Francisco Hernandez-Ilizaturri, MD	Roswell Park Cancer Institute	Ofatumumab in combination with high dose cytarabine chemoimmunotherapy for patients with newly diagnosed Mantle Cell Lymphoma (MCL)
Shuo Ma, MD, PhD	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	Correlative Studies in Conjunction with A Phase II Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Clinical Studies for Axitinib

INVESTIGATOR	MEMBER INSTITUTION	STUDY
Alan L. Ho, MD, PhD	Memorial Sloan-Kettering Cancer Center	A Phase II Study of Axitinib (AG-013736) in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Nikhil I. Khushalani, MD	Roswell Park Cancer Institute	Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma
Jonathan Strosberg, MD	H. Lee Moffitt Cancer Center & Research Institute	A Phase II Study of Axitinib in Advanced Carcinoid Tumors
Francis P. Worden, MD	University of Michigan Comprehensive Cancer Center	Phase II Trial Evaluating Axitinib in Patients with Unresetable, Recurrent or Metastatic Head and Neck Cancer

E-mail

Mark A A Size